Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lexeo Therapeutics Inc. (LXEO:NASDAQ), powered by AI.
Lexeo Therapeutics Inc. is currently trading at $4.75. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lexeo Therapeutics Inc. on Alpha Lenz.
View Lexeo Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Lexeo Therapeutics Inc.'s ROE is -55.0%. Explore profitability and growth together.”
Ask for details →Lexeo Therapeutics Inc. is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies for complex diseases. Established with a mission to transform lives through groundbreaking advancements, Lexeo Therapeutics is primarily engaged in addressing genetic disorders that have limited treatment options. The company emphasizes its work in the fields of cardiology, ophthalmology, and neurodegenerative diseases, placing a strong focus on precision medicine to deliver targeted therapeutic solutions. Lexeo Therapeutics holds a distinct position in the biotechnology industry by leveraging advanced technologies in gene therapy to pioneer treatments that aim to correct or replace defective genes at the root cause of diseases. This approach has significant implications not only for patient outcomes but also for expanding the horizons of genetic medicine. In the financial market, Lexeo Therapeutics Inc. is recognized for its potential to contribute to the advancement of healthcare solutions, playing a crucial role in the ongoing evolution of biopharmaceutical innovation and development.
“Lexeo Therapeutics Inc.'s ROE is -55.0%. Explore profitability and growth together.”
Ask for details →Lexeo Therapeutics Inc. (ticker: LXEO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 61 employees.
The current price is $4.75 with a P/E ratio of -x and P/B of -x.
ROE is -55.00%.